Philips Q2 2025 slides: Sales return to growth as margins expand, outlook raised

Royal Philips reported a strong Q2 2025, marking a return to 1% comparable sales growth and significant profitability improvements, with adjusted EBITA margin expanding 130 basis points to 12.4% and free cash flow recovering to €230 million. This performance, driven by productivity initiatives and robust growth in the Personal Health segment, prompted the company to upgrade its full-year 2025 adjusted EBITA margin and free cash flow outlook, signaling increased confidence despite varied segment performance.

Analysis

Royal Philips (PHIA) demonstrated a significant operational recovery in its Q2 2025 results, reversing the negative trend from the first quarter. The company reported a 1% increase in comparable sales to €4,338 million and a notable 130 basis point expansion in its adjusted EBITA margin to 12.4%. This profitability improvement was primarily fueled by €344 million in year-to-date productivity savings and pricing actions, which successfully offset cost headwinds. A critical highlight is the dramatic turnaround in free cash flow to a positive €230 million, a stark contrast to the cash outflow in Q1 that was heavily impacted by the €1 billion Respironics litigation settlement. The performance was uneven across divisions; the Personal Health segment was the clear growth engine with 6% comparable sales growth driven by product innovation, while the larger Diagnosis & Treatment and Connected Care segments both posted 1% sales declines, attributed to a high comparison base. Despite the sales dip, strong double-digit order intake in Diagnosis & Treatment suggests a potentially strengthening pipeline. Reflecting this improved performance and a more favorable tariff environment, management upgraded its full-year 2025 outlook, raising the adjusted EBITA margin target by 50 basis points to 11.3-11.8% and significantly increasing its free cash flow guidance from 'slightly positive' to €0.2-€0.4 billion.

Key Decisions for Investors

• Investors should recognize the positive inflection point, as the upgraded full-year guidance for EBITA margin and free cash flow signals that the company's turnaround strategy and productivity measures are yielding tangible results.
• It is crucial to monitor the sales conversion from the strong order book in the Diagnosis & Treatment segment, as sustained underperformance in this and the Connected Care division remains the key risk to offsetting the robust growth in Personal Health.
• Given the substantial improvement in free cash flow post-litigation settlement and the reduced tariff impact, it may be prudent to re-evaluate the stock's risk profile, as the enhanced financial stability could support a higher valuation.